DEA Cracks Down on Weird Ketamine Cousin, Schedules It Tight
Published Date: 1/20/2026
Proposed Rule
Summary
Starting February 19, 2026, 2-fluorodeschloroketamine (2-FDCK) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even possesses 2-FDCK, who will now face strict rules and possible penalties. The move helps keep this new drug off the streets while the government figures out the long-term plan.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
2‑FDCK Placed in Schedule I
Starting when the temporary order is published on or after February 19, 2026, 2‑fluorodeschloroketamine (2‑FDCK) — including its salts and isomers — will be listed in Schedule I of the Controlled Substances Act. That means people who manufacture, distribute, import, export, sell, or possess 2‑FDCK will be subject to the regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances.
Research & Instruction Restricted
Once the temporary Schedule I order is in effect (on or after February 19, 2026), research, instructional activities, and chemical analysis involving 2‑FDCK will be subject to the regulatory controls that govern Schedule I substances. Institutions, laboratories, instructors, and researchers handling or proposing to handle 2‑FDCK will need to comply with Schedule I requirements and will be subject to administrative, civil, and criminal sanctions if they do not.
Temporary Order Is Not Judicially Reviewable
The temporary scheduling order for 2‑FDCK will not be subject to judicial review while it remains in effect. The order will be issued under 21 U.S.C. 811(h) and will take effect on publication (on or after February 19, 2026) and remain for two years, with possible extension of one additional year.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-00934 — Amendment of Class E Airspace; Covington, KY
The FAA wants to update the Class E airspace around Covington, KY because a key navigation beacon nearby is being shut down. This change helps keep flight rules safe and up to date for pilots flying with instruments. If you have thoughts, speak up by March 6, 2026—no costs or delays expected for travelers or airlines.
Next: 2026-00959 — Amendments to Definitions and Related Provisions Under the Randolph-Sheppard Vending Facility Program; Withdrawal
The Department of Education has decided to cancel proposed changes to the Randolph-Sheppard Vending Facility Program rules, which would have updated key definitions like “vending machine” and added new ones. This affects blind vendors and state agencies who use these rules to run vending facilities. No new rules or costs will happen now, and the withdrawal is official as of January 20, 2026.